MDM2 and cancer: Interestingly, despite the differences in cancer types (such as bladder carcinoma, triple-negative breast cancer, endometrial stromal sarcoma, lung adenocarcinoma, and gastroesophageal junction adenocarcinoma), ICI types (including PD1 and PD-L1 blockade monotherapy), and treatment lines (first-line or nonfirst-line ICI treatment), none of the patients with MDM2 amplification responded positively to ICIs.